A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

Otsuka Pharmaceutical Development & Commercialization, Inc.44 enrolled

Overview

Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use. The DMS is being developed as a healthcare management tool to precisely measure medication adherence and to potentially enhance adherence.

The advancements in the treatment of mental health patients with DMS will enable healthcare professionals to assess suboptimal adherence and make more informed treatment decisions. In addition to these improvements, it will also provide a platform for engagement between participants, healthcare professionals, and caregivers/support persons. Participants who entered the trial were treated with one of the oral atypical antipsychotics defined in the trial (aripiprazole, olanzapine, quetiapine, or risperidone \[though no participant took risperidone in this trial\]). The treatment medication decision was determined by the healthcare professionals.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

Schizophrenia Schizoaffective Disorder First Episode Psychosis

Interventions

Digital Medicine SystemDEVICE

DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \[Disposable Wearable Sensor Version 5\]); proprietary medical software (a local and remote computing application).

AripiprazoleDRUG

Dosage determined by the healthcare professionals.

OlanzapineDRUG

Dosage determined by the healthcare professionals.

QuetiapineDRUG

Dosage determined by the healthcare professionals.

RisperidoneDRUG

Dosage determined by the healthcare professionals.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participant was prescribed aripiprazole, olanzapine, quetiapine, or risperidone. * Participant possessed a smartphone, or a smartphone provided by the Sponsor, and was willing to download and interact with the DMS app. * Skin on the anterior chest just above the lower edge of the rib cage was free of any dermatological problems (for example, open wounds, warts, rashes, atopic dermatitis). Exclusion Criteria: * Participant with a known allergy to adhesive tape or any pertinent components of the patch or CoE product. * Prisoners could not be enrolled into this trial. * Participant who was hospitalized due to mental or physical illness (inpatient) at the time of screening/baseline. * Any participant who, through religious or lifestyle choices, would not take gelatin capsules. * Female of childbearing potential who was breast-feeding and/or who had a positive pregnancy test result prior to receiving trial enrollment, or who planned to become pregnancy during the trial.

Locations (5)

Clinical Trial Site

Chertsey, United Kingdom

Clinical Trial Site

London, United Kingdom

Clinical Trial Site

Newcastle upon Tyne, United Kingdom

Clinical Trial Site

Oxford, United Kingdom

Clinical Trial Site

Southampton, United Kingdom

Outcomes

Primary Outcomes

Percentage Of Days With Good Patch Coverage

The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (miniature ingestible event marker in tablet \[MIT\]). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Good patch coverage for a specific day was defined as having either at least 80% patch data available (80% of the day the patch was worn and data was collected as noted via the accelerometer channel) or the MIT was detected within the 24-hour period, for each day while the participant was in the trial. The percentage of days was calculated as the number of days with good patch coverage divided by the total number of trial days for each participant. Descriptive statistics were performed for this outcome measure.

Time frame: Up to 8 weeks

Secondary Outcomes

Participant Adherence

The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (MIT). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Participant adherence was measured as the detected MITs over the expected MITs ingested during the trial days with good patch coverage. The more the participant successfully engaged in a number of processes across the 8-week trial, the greater the measured adherence. Descriptive statistics were performed for this outcome measure.

Time frame: Up to 8 weeks